HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LUCD
Lucid Diagnostics Inc.
There isn't enough reported data to score LUCD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LUCD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
LUCD's revenue is currently stable, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LUCD PE Valuation
LUCD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LUCD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LUCD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
LUCD has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus LUCD down 177%.
LUCD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$0.87 | +$0.26 |
| Q2 2025 | -$1.02 | +$0.20 |
| Q1 2025 | -$1.17 | +$0.09 |
| Q4 2024 | -$1.05 | +$0.21 |
| Q3 2024 | -$1.13 | +$0.29 |
| Q2 2024 | -$1.22 | +$0.25 |
| Q1 2024 | -$1.26 | +$0.35 |
| Q4 2023 | -$1.26 | +$0.30 |
LUCD is still losing money, but less than at its worst: $0.87 per share over the past year, against $1.61 at its worst in early 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LUCD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over LUCD on profitability, with a higher operating margin.
LUCD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -0.7% |
| Q2 2026 | $1.5M | +27% |
| Q1 2026 | $1.3M | +52% |
| Q4 2025 | $1.5M | +26% |
| Q3 2025 | $1.2M | +3.3% |
| Q2 2025 | $1.2M | +19% |
| Q1 2025 | $828K | -17% |
| Q4 2024 | $1.2M | +15% |
LUCD's revenue is growing: $1M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1020% | -49 points |
| Q2 2026 | -868% | +110 points |
| Q1 2026 | -964% | +544 points |
| Q4 2025 | -932% | +102 points |
| Q3 2025 | -971% | +27 points |
| Q2 2025 | -979% | +168 points |
| Q1 2025 | -1508% | -430 points |
| Q4 2024 | -1034% | +67 points |
LUCD's operating margin was −1020% last quarter, down 49 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
LUCD has the stronger cash trend. Its trailing FCF is down 56% versus its history, compared with HIMS at down 84%.
LUCD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.6M | -$4.7M |
| Q2 2026 | -$11.3M | -$769K |
| Q1 2026 | -$12.3M | +$149K |
| Q3 2025 | -$10.9M | -$718K |
| Q2 2025 | -$10.5M | +$933K |
| Q1 2025 | -$12.5M | +$147K |
| Q1 2024 | -$12.6M | -$5.6M |
| Q1 2023 | -$7.1M | -$1.1M |
LUCD has burned cash in almost every quarter: −$50M over the past year, against −$43M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LUCD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LUCD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.3% | +7.8M shares |
| 1 year | +93% | +92M shares |
| 3 years | +366% | +150M shares |
| 5 years | +416% | +154M shares |
| Available history | +416% | +154M shares |
LUCD has 191M diluted shares, up 93% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LUCD Net Leverage
LUCD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LUCD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 14.0 | Oversold |
LUCD's weekly RSI is 24 (oversold) and its Stochastic is 14 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LUCD PE vs Healthcare Sector
LUCD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LUCD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.52 | 19% below |
| 20 week MA | $0.77 | 45% below |
| 50 week MA | $1.00 | 58% below |
| 100 week MA | $1.09 | 61% below |
| 200 week MA | $1.14 | 63% below |
LUCD is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over LUCD on returns for 2026, with the stronger performance.
LUCD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.35 | $4.92 | -47% |
| 2022 | $4.92 | $1.40 | -72% |
| 2023 | $1.40 | $1.41 | +0.7% |
| 2024 | $1.41 | $0.79 | -44% |
| 2025 | $0.79 | $1.09 | +38% |
| 2026 YTD | $1.09 | $0.42 | -61% |
LUCD has finished lower in three of the last five years. It's down 61% so far in 2026.